Retrograde Versus Antegrade Approach for the Endovascular Treatment of Symptomatic Femoropopliteal Disease: Results of the 2-Year Follow Up
Endovascular Versus Bypass
Keywords:Superficial femoral artery, endovascular treatment, antegrade, retrograde, primary patency, complication
Objective: To compare the antegrade and retrograde approaches, in terms of access site complications and long-term patency in subjects undergoing EVT for symptomatic SFA or popliteal artery stenosis or occlusions.
Methods: All consecutive patients who underwent retrograde recanalization for partial stenosis or chronic total occlusion of the SFA or PA at 2 centers were enrolled in this retrospective analysis. Subjects were divided into 2 groups, according to the approach selected for EVT as antegrade approach group or retrograde approach group. The rate of primary patency, which was defined as the lack of restenosis at the target lesion, was the primary outcome measure, during the follow-up evaluations. The rate of procedural complications, including hematoma, bleeding, and distal embolism, were secondary outcome measures.
Results: A significant improvement occurred in ABI, following the intervention in both the antegrade approach group [0.7 (0.3 - 1.1) versus 0.85 (0.4 - 1.3), P < 0.001] and retrograde approach group [0.5 (0.3 - 1.1) versus 0.8 (0.3 - 1.3), P < .001]. The primary patency rate at the 1st, 6th, 12th and 24th months of the intervention in the antegrade approach group were 94.85%, 83.82%, 74.26%, and 66.91%, respectively. The primary patency rate at the 1st, 6th, 12th, and 24th months of the intervention in the retrograde approach group were 93.33%, 86.67%, 84.44%, and 71.11%, respectively. The groups were similar with respect to the primary patency rates. The rate of complications, including hematoma, bleeding, and distal embolization was similar in the 2 groups.
Conclusion: Antegrade approach and retrograde approach provide a similar safety profile in the EVT of SFA and popliteal artery stenosis and occlusion. The primary patency rates at the 1st, 6th, 12th, and 24th months of follow up also were similar in the 2 groups. However, the significant difference in the lesion characteristics of the subjects undergoing retrograde or antegrade approach complicates the ability to reach a clear conclusion, regarding the superiority of one technique over the other.
Drachman DE. 2019. Endovascular Treatment of the Superficial Femoral Artery: When Nothing Is Actually Quite Something. J Am Coll Cardiol 73(6):680-3.
Dumantepe M. 2017. Retrograde Popliteal Access to Percutaneous Peripheral Intervention for Chronic Total Occlusion of Superficial Femoral Arteries. Vascular and endovascular surgery. 51(5):240-6.
Fanelli F, Lucatelli P, Allegritti M, Corona M, Rossi P, Passariello R. 2011. Retrograde popliteal access in the supine patient for recanalization of the superficial femoral artery: initial results. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists. 18(4):503-9.
Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. 2009. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. Journal of vascular surgery. 50(1):54-60.
Marone EM, Rinaldi LF, Argenteri A, Chiesa R. 2018. Current treatment of superficial femoral artery disease: a national survey. J Cardiovasc Surg (Torino). 59(5):755-6.
Miller AJ, Takahashi EA, Harmsen WS, Mara KC, Misra S. 2017. Treatment of Superficial Femoral Artery Restenosis. Journal of vascular and interventional radiology: JVIR. 28(12):1681-6.
Murakami A. 2018. Towards the Application of Endovascular Treatment for Superficial Femoral Artery. Circ J. 82(5):1253-4.
Niazi K, Tukaye DN. 2017. Challenges of Stent Restenosis in Superficial Femoral and Popliteal Artery Disease. JACC Cardiovasc Interv. 10(20):2124-5.
Noory E, Rastan A, Schwarzwalder U, Sixt S, Beschorner U, Burgelin K, et al. 2009. Retrograde transpopliteal recanalization of chronic superficial femoral artery occlusion after failed re-entry during antegrade subintimal angioplasty. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists. 16(5):619-23.
Perera GB, Lyden SP. 2007. Current trends in lower extremity revascularization. Surgical Clinics of North America. 87(5):1135-47.
Powell RJ. 2008. Endovascular treatment in the superficial femoral artery: which devices, where? Seminars in vascular surgery. 21(4):180-5.
Pua U. 2015. Profunda anchor technique for ipsilateral antegrade approach in endovascular treatment of superficial femoral artery ostial occlusion. Cardiovasc Intervent Radiol. 38(2):453-6.
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. 2015. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. New England Journal of Medicine. 373(2):145-53.
Schmieder GC, Panneton JM. 2008. Endovascular superficial femoral artery treatment: can it be as good as bypass? Seminars in vascular surgery. 21(4):186-94.
Schneider PA. 2017. Evolution and current use of technology for superficial femoral and popliteal artery interventions for claudication. J Vasc Surg. 66(3):916-23.
Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D, et al. 2018. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN. PACT SFA randomized trial. Circulation: Cardiovascular Interventions. 11(1):e005891.
Stavroulakis K, Argyriou A, Watts M, Varghese JJ, Estes BA, Torsello G, et al. 2019. How to deal with calcium in the superficial femoral artery. J Cardiovasc Surg (Torino). 60(5):572-81.
Tokuda T, Hirano K, Muramatsu T, Tsukahara R, Nakano M. 2014. A sheathless retrograde approach via the popliteal artery is useful and safe for treating chronic total occlusions in the superficial femoral artery. Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists. 21(2):289-95.
Ueshima D, Ashikaga T, Shimura T, Hatano Y, Sasaoka T, Kurihara K, et al. 2015. Popliteal retrograde approach is effective and safe for superficial femoral artery chronic total occlusion. Annals of Vascular Diseases. 8(3):220-6.
Wojtasik-Bakalarz J, Arif S, Chyrchel M, Rakowski T, Bartus K, Dudek D, et al. 2017. Twelve months follow-up after retrograde recanalization of superficial femoral artery chronic total occlusion. Postepy Kardiol Interwencyjnej. 13(1):47-52.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).